FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Effects of Quadriceps Strengthening Exercise with Blood Flow Restriction on Knee Angular Velocity, Strength, and Balance in Fencers. PMID 42318262 · J Sports Sci Med · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of Acceptance and Commitment Therapy on Death Anxiety in Cancer Survivors: A Randomized Controlled Trial. PMID 42317021 · Psychooncology · 2026-Jun The study is a randomized controlled trial in cancer survivors, but it evaluates a psychotherapy (ACT), not a drug-containing intervention. The primary endpoint is death anxiety, a quality-of-life measure, not a time-to-event efficacy endpoint (e.g., OS, PFS). It is not a Phase III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mindfulness-Based Stress Reduction for Breast Cancer Survivors (MBSR[BC]) Improves Self-Reported Optimism. PMID 42316845 · Psychooncology · 2026-Jun The study is an oncology RCT in human breast cancer survivors with original results. However, it is excluded because: 1) The intervention is non-pharmacological (MBSR), not a drug-containing intervention. 2) The endpoints are psychosocial outcomes, not time-to-event efficacy endpoints. 3) The trial phase is not established as Phase III or definitive. 4) The analysis is described as secondary/exploratory. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Phase 3 Trial of Oral Prednisolone Administration Versus Local Triamcinolone Injection Therapy for Esophageal Stricture Prevention After Extensive Endoscopic Submucosal Dissection (JCOG1217). PMID 42313516 · Dig Endosc · 2026-Jun The trial is a randomized Phase III study in a human oncology context with a time-to-event endpoint. However, the drug intervention (prednisolone vs. triamcinolone) is for the prevention of a post-procedural complication (esophageal stricture), not for treating the underlying malignant neoplasm. The efficacy endpoint (stricture-free survival) is not a direct oncological efficacy endpoint (like OS, PFS, DFS). Therefore, it does not meet the core criterion of being a trial of a drug-containing intervention for efficacy against the cancer. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Analysis of Viral Blips Through Week 192 of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Studies of Doravirine-Based Regimens in Adults Living With Previously Untreated HIV-1. PMID 42281892 · Open Forum Infect Dis · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial. PMID 42273802 · Alzheimers Dement · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial. PMID 42272346 · United European Gastroenterol J · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Oral Anticoagulation in Systemic Sclerosis-Related Pulmonary Arterial Hypertension-Results From the SPHInX Study. PMID 42266819 · Pulm Circ · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study. PMID 42257510 · Eur J Neurol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China. PMID 42256683 · EClinicalMedicine · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France). PMID 42256682 · EClinicalMedicine · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Zoliflodacin for uncomplicated gonorrhea: clinical evidence and implications beyond ceftriaxone plus azithromycin. PMID 42254149 · Ann Med Surg (Lond) · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study. PMID 42253638 · EJHaem · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus. PMID 42253408 · Metabol Open · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Baclofen Modulates Neural Intrinsic Functional Connectivity in Treatment-Seeking Individuals With Alcohol Use Disorder. PMID 42246466 · Alcohol Clin Exp Res (Hoboken) · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Efficacy of Nicotinamide in Maintaining Mean Deviation in Glaucoma: A Systematic Review. PMID 42244899 · Cureus · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Dietary inflammatory index and unfavorable dietary patterns associated with ischemic stroke in China. PMID 42242853 · Asia Pac J Clin Nutr · 2026-Jun The study is an oncology randomized Phase III trial with primary results, but it does not meet the inclusion criteria because the intervention is a non-drug nutritional product (FSMP) and the primary endpoint is not a time-to-event efficacy measure (it is a change in a biochemical marker). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial. PMID 42225102 · Lancet Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical implications of skincare: lessons from placebo-controlled dermatology trials. PMID 42222690 · Skin Health Dis · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Personalised and Gamified Digital Decision Aid for Colorectal Cancer Screening: A Randomised Controlled Pilot Study. PMID 42216438 · Cancer Med · 2026-Jun This is a randomized pilot study of a digital decision aid for colorectal cancer screening, not a drug intervention trial, and does not have a time-to-event efficacy endpoint. It fails the core eligibility criteria of having a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis. PMID 42206806 · J Comp Eff Res · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of an internal traction device in colorectal endoscopic submucosal dissection: a multicenter randomized controlled trial. PMID 42191957 · Surg Endosc · 2026-Jun 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Safety-Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials. PMID 42186850 · Stat Med · 2026-Jun The record is a methodological study proposing and simulating a new trial design (SAFER), not an original formal-result report of a specific Phase III trial. While it references a Phase III trial (CAPP-IT) and is oncology-related, it does not present primary efficacy results (time-to-event or otherwise) for that or any trial. |
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol. PMID 42179865 · Contemp Clin Trials Commun · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of Fospropofol on intraoperative hemodynamics in patients undergoing Supratentorial tumor resection: A randomized controlled trial. PMID 42176429 · J Clin Anesth · 2026-Jun The study is a randomized, human, oncology trial with a drug intervention (fospropofol vs. propofol) and original results. However, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary outcome is a hemodynamic measure (area under the threshold for mean arterial pressure <65 mmHg), and secondary outcomes are other perioperative clinical measurements, not oncology efficacy endpoints. Phase is not specified as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies. PMID 42176145 · Inflammopharmacology · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Palbociclib in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review. PMID 42173733 · Clin Breast Cancer · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Postmastectomy Radiotherapy With Immediate Implant Reconstruction: Treatment Fractionation, Implant Plane, and Clinical Outcomes. PMID 42173060 · Clin Breast Cancer · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Estimated efficacy of the adjuvanted RSVPreF3 vaccine against diverse and worldwide predominant RSV strains, irrespective of RSV F protein variation: results of a post-hoc analysis from the AReSVi-006 trial. PMID 42172919 · EBioMedicine · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Smoldering Multiple Myeloma: From Clinical to Immunogenomic Risk Stratification and Therapeutic Implications of Early Intervention. PMID 42172562 · Am Soc Clin Oncol Educ Book · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials. PMID 42161782 · Clin Breast Cancer · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Covered self-expandable metal stents in benign biliary strictures caused by chronic pancreatitis: a randomized controlled trial of 6 versus 12 months of stenting. PMID 42151467 · Surg Endosc · 2026-Jun 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial. PMID 42150582 · Lancet Respir Med · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials. PMID 42144019 · Lancet Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study. PMID 42144018 · Lancet Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Regulatory approval of new oncology drugs, 2020-2024: A comparative analysis of FDA, EMA, and ANVISA. PMID 42142604 · J Cancer Policy · 2026-Jun The record is a comparative analysis of oncology drug approvals by regulatory agencies (FDA, EMA, ANVISA), not an original report of a randomized clinical trial with a time-to-event efficacy endpoint. It does not meet the criterion of being an original result report of a trial. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Longitudinal trajectories of anxiety and depression in patients with endometrial cancer or atypical endometrial hyperplasia undergoing fertility-sparing treatment. PMID 42139817 · Gynecol Oncol · 2026-Jun Eligible for oncology, human, randomized, drug intervention, and original result. Excluded because the primary endpoint is psychological outcomes (anxiety/depression), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy. PMID 42134381 · Lancet Oncol · 2026-Jun The record describes a Phase III randomized controlled trial in human oncology (breast cancer) with a time-to-event endpoint (ipsilateral breast recurrence). However, the intervention is a radiotherapy schedule (hypofractionated radiation), not a drug-containing intervention. The inclusion criteria explicitly require a drug-containing intervention, which is not met. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial. PMID 42128444 · Neurol Clin Pract · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC. PMID 42120266 · Clin Lung Cancer · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Distal margin length after neoadjuvant chemoradiotherapy has no prognostic impact in low rectal cancer once the margin is microscopically negative: A multicentre equivalence analysis. PMID 42114353 · Eur J Surg Oncol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Twenty-Three-Year Benefits of Sigmoidoscopy Screening for Colorectal Cancer : A Randomized Trial. PMID 42114097 · Ann Intern Med · 2026-Jun The record describes a randomized, population-based cancer screening trial evaluating sigmoidoscopy for colorectal cancer incidence and mortality reduction. While it is oncology and reports long-term results, it does not meet the required criteria: it is not a Phase III/IIIb or Phase II/III trial (no drug intervention is involved), and it does not report a primary/time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) for a drug. The outcomes are cancer incidence and mortality risk differences, not time-to-event analyses with Kaplan-Meier curves or hazard ratios as primary endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis. PMID 42110973 · JBMR Plus · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy. PMID 42104840 · Circ Heart Fail · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. PMID 42086981 · Nat Med · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular outcomes of novel SGLT2 inhibitors in patients with type 2 diabetes: a network meta-analysis of bexagliflozin, ertugliflozin and sotagliflozin. PMID 42086086 · Diabetes Res Clin Pract · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1. PMID 42082865 · J Endocrinol Invest · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia. PMID 42077391 · Blood Red Cells Iron · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Genotype distribution of human papillomavirus (HPV) types in oral gargle specimens among men living with HIV in Mexico, Brazil, and Puerto Rico: A cross-sectional study. PMID 42070588 · J Infect · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial. PMID 42070197 · Dermatol Ther (Heidelb) · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |